Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (Q43707358)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group |
scientific article |
Statements
1 reference
Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (English)
1 reference
Shepherd FA
1 reference
Dancey J
1 reference
Arnold A
1 reference
Neville A
1 reference
Rusthoven J
1 reference
Johnson RD
1 reference
Fisher B
1 reference
Eisenhauer E
1 reference
1 August 2001
1 reference
Identifiers
1 reference